Tissue Regenix Group plc (TRX) ORD GBP0.001

Tissue Regenix Group plc is a medical device company in regenerative medicine. The Company is focused on the development of regenerative products utilizing its two platform technologies, dCELL, addressing soft tissue needs, and BioRinse, providing sterile bone allografts. It is focused on helping to transform the treatment of patients into key surgical applications: biosurgery, orthopedics (sports medicine/spine), dental, general, plastic surgery, urology/gynecology, ophthalmology, and cardiac. Its decellularization (dCELL) technology platform removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold, which is not rejected by the patient’s body, and can then be used to repair diseased or damaged body parts. Its BioRinse technology platform is primarily utilized to provide sterile tissue prepared in a manner to minimize the negative effects of processing. Its products include DermaPure, OrthoPure XT, ConCelltrate 100 and others.